| Literature DB >> 21035331 |
Sabina Pecchi1, Paul A Renhowe, Clarke Taylor, Susan Kaufman, Hanne Merritt, Marion Wiesmann, Kevin R Shoemaker, Mark S Knapp, Elizabeth Ornelas, Thomas F Hendrickson, Wendy Fantl, Charles F Voliva.
Abstract
PI3 Kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration, and differentiation. The PI3 kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations, and PTEN phosphatase deletion. PI3K inhibitors represent therefore an attractive therapeutic modality for cancer treatment. Herein we describe a novel series of PI3K inhibitors sharing a pyrimidine core and showing significant potency against class I PI3 kinases in the biochemical assay and in cells. The discovery, synthesis and SAR of this chemotype are described.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21035331 DOI: 10.1016/j.bmcl.2010.10.021
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823